Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
80%(4 trials)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
2
40%
Ph phase_4
2
40%

Phase Distribution

2

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 42 (40.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

NCT05755620
completedphase_1

Flublok or Fluzone With Advax-CpG55.2 or AF03

NCT03945825
completedphase_4

Development of Childhood Anti-Influenza Immunity

NCT03673345
completedphase_4

Age and Response to Flu Vaccines

NCT03328325
completedphase_2

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

NCT03318315

Clinical Trials (5)

Showing 5 of 5 trials
NCT05755620Phase 1

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

Completed
NCT03945825Phase 1

Flublok or Fluzone With Advax-CpG55.2 or AF03

Completed
NCT03673345Phase 4

Development of Childhood Anti-Influenza Immunity

Completed
NCT03328325Phase 4

Age and Response to Flu Vaccines

Completed
NCT03318315Phase 2

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Completed

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5